A prospective cohort study in 66 patients with end-stage renal disease was conducted to determine the link between renal and coronary heart diseases.
For patients with type 2 diabetes, long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with fracture risk.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Researchers compared 3 classes of antihypertensive medication to determine hip and pelvic fracture risk in users vs nonusers.
Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.
Heavy cannabis users have lower bone density compared to cigarette smokers.
Summer levels of serum 25-hydroxyvitamin D are associated with bone mineral density of the total hip.
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other health care professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis.
According to results from the TECOS trial, sitagliptin is not linked to an increased risk for fractures in patients with diabetes.
In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo.